Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | TNBC | Basal A | Etoposide | TOP2 | TOP | 66.7 | uM | 5904.074 | 0.2499 | -0.5245 | 0.9654 | |
| SK-BR-3 | HER2amp | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7526.084 | 0.4871 | 0.3446 | 1.8115 | |
| SUM1315MO2 | TNBC | Basal B | Methotrexate | DHFR | Metabolism | 66.7 | uM | 9044.084 | 1.0027 | 1.0113 | 0.4769 | |
| HCC70 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14739.203 | 0.0109 | -0.9973 | 0.6862 | |
| MDA-MB-453 | TNBC | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7517.084 | 0.8118 | 0.7247 | 1.4076 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14845.203 | 0.0698 | -0.9548 | 0.7023 | |
| BT-474 | HER2amp | Luminal | Etoposide | TOP2 | TOP | 66.7 | uM | 5905.074 | 0.5789 | 0.0629 | 0.8648 | |
| MDA-MB-453 | TNBC | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7518.084 | 0.8321 | 0.7409 | 1.3244 | |
| SUM149PT | TNBC | Basal B | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7530.085 | 0.9154 | 0.9188 | 2.1343 | |
| SUM229PE | TNBC | - | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7537.084 | 0.7494 | 0.7138 | 1.8684 | |
| HCC38 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14909.203 | 0.0094 | -0.9320 | 1.3791 | |
| MDA-MB-361 | HER2amp | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7507.084 | 0.5197 | 0.1154 | 1.1207 | |
| HCC1419 | HER2amp | Luminal | FTase Inhibitor I | Ftase | MAPK | 66.7 | uM | 12001.167 | 0.8952 | 0.6221 | 0.5287 | |
| MDA-MB-361 | HER2amp | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7508.084 | 0.4382 | -0.3097 | 0.7756 | |
| SUM149PT | TNBC | Basal B | AS-252424 | PI3K | PI3K | 66.7 | uM | 11937.158 | 0.4161 | 0.3519 | 2.2386 | |
| SUM159PT | TNBC | Basal B | AS-252424 | PI3K | PI3K | 66.7 | uM | 10520.141 | 0.2555 | 0.3744 | 3.6374 | |
| MDA-MB-361 | HER2amp | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7506.085 | 0.6492 | 0.3497 | 1.0985 | |
| MDA-MB-415 | HR+ | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7510.084 | 0.9351 | 0.8517 | 0.8702 | |
| MDA-MB-157 | TNBC | Basal B | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7498.084 | 0.7413 | 0.5502 | 1.1749 | |
| 184B5 | NM | Basal | Erlotinib | EGFR | ErbB | 66.7 | uM | 5896.091 | 0.4081 | 0.0999 | 1.4988 | |
| MDA-MB-175-VII | HR+ | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7499.084 | 0.9204 | 0.8028 | 0.7991 | |
| MDA-MB-134-VI | HR+ | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7494.084 | 0.9490 | 0.9007 | 1.0275 | |
| MDA-MB-157 | TNBC | Basal B | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7496.085 | 0.5030 | 0.0553 | 1.0748 | |
| MDA-MB-175-VII | HR+ | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7500.084 | 1.0786 | 1.2780 | 0.5811 | |
| MCF12A | NM | Basal B | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7490.085 | 0.3687 | 0.3581 | 2.5778 |